Cyntellect Snares First Customer for HT Cell-Based Drug-Screening Applications | GenomeWeb

Fresh off its official incorporation as a company, San Diego-based Cyntellect announced last week that it has entered into a research agreement with Japanese drug maker Daiichi, which will use Cyntellect’s high-throughput cell imaging and laser-based manipulation technology for cell-based drug discovery.

Under the terms of the agreement, Cyntellect will design, configure, and run cell-based assays on its LEAP (Laser-Enabled Analysis and Processing) platform against a compound collection provided by Daiichi.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.